Antidepressant Switching Among Adherent Patients Treated for Depression

Marcus, Steven C.; Hassan, Mariam; Olfson, Mark

doi:10.1176/appi.ps.60.5.617

Cited by 12 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is unclear if some of the differences observed here were due to the fact that duloxetine was still the newer antidepressant at this time and whether the observed factors would persist if later data was utilized. Greater clinical severity and low initial dosing have been found to be factors predicting earlier antidepressant switching [24] and such patients may have preferentially tried the newer medication. We did not assess initial dose in this work and additional confirmatory work utilizing more recent data is warranted.…”

Section: Discussionmentioning

confidence: 99%

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

Zhao

Robinson

et al. 2011

BMC Psychiatry

View full text Add to dashboard Cite

BackgroundDuloxetine and venlafaxine extended release (venlafaxine XR) are SNRIs indicated for the treatment of MDD. This study addresses whether duloxetine and venlafaxine XR are interchangeable in their patterns of use with patients who are depressed or are used more selectively based on treatment history, background characteristics, and presenting symptoms.MethodsThis was a retrospective analysis of an administrative insurance claims database. We studied patients in managed care with major depressive disorder (MDD) treated with duloxetine or venlafaxine XR. Predictors of treatment and cost were assessed using Chi-square and logistic regression analyses of demographics and past-year medication use and comorbidities.ResultsPatients with MDD treated with duloxetine (n = 9,641) versus venlafaxine XR (n = 8,514) tended to be older, slightly more likely to be female, and treated by a psychiatrist (P < 0.0001). In the prior year, more duloxetine patients (vs. venlafaxine XR) received ≥3 unique antidepressants (20.8% vs. 16.6%), ≥3 unique pain medications (25.5% vs. 15.6%), and had ≥8 unique diagnosed comorbid medical and psychiatric conditions (38.6% vs. 29.1%). The prior 6-month total health care costs were $1,731 higher for duloxetine than for venlafaxine XR and declined for both medications in the 6 months after treatment began. Logistic regression analysis revealed that 61% of duloxetine patients and 61% of venlafaxine XR patients were predictable from prior patient and treatment factors.ConclusionsPatients with MDD treated with duloxetine tended to have a more complex and costly antecedent clinical presentation compared with venlafaxine XR patients, suggesting that physicians do not use the medications interchangeably.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

Zhao

Robinson

et al. 2011

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…The classes of antidepressants used as first-line agents among patients starting treatment for a new episode of depression appear to be new generation ones in many parts of the world. In USA a nationally representative survey of medical service utilization between 1996 and 2001 indicated that 75% of patients who initiated antidepressant treatment for depression started with selective serotonin reuptake inhibitors (SSRIs) or serotonin and noradrenaline reuptake inhibitors (SNRIs) (Olfson et al, 2006), Medical and pharmacy claims database in more recent years also report similar figures (78% between 2001 and 2004 (Robinson et al, 2006), or 87% between 2001(Marcus et al, 2009). In Europe a cohort study of consecutive patients commencing antidepressant treatment at over 400 primary and secondary care clinics indicated that across 12 countries, 63% started with SSRIs and 14% with SNRIs (Bauer et al, 2008).…”

mentioning

confidence: 96%

“…However, the clinicians' actual behaviors may or may not be the same as what they say they do. For example, among patients who initiated antidepressant therapy and who continued treatment for more than 3 months, switching antidepressants took place only in 9% (Marcus et al, 2009). To the best of the present authors' knowledge no other study looked at how switching and other second-line strategies are employed in the clinical practices.…”

mentioning

confidence: 97%

Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database

Furukawa

Onishi

Hinotsu

et al. 2013

Journal of Affective Disorders

View full text Add to dashboard Cite

“…The support for the predicted relationship between SLC6A4 and trimipramine stems from the similarity to the two drugs directly related to the gene, in the text-mining-derived network (mirtazapine and clomipramine), and from the similarity to the drug carbamazapine, which is related in the text-mining-derived network to the CALR gene, found to interact with SLC6A4 in the InWeb network. Mirtazapine is an antidepressant used for the treatment of moderate to severe depression, and has a very similar set of indications as trimipramine 18 . Of the drugs that co-occur in the literature with SLC6A4, the one that is most similar in structure to trimipramine is clomipramine.…”

Section: Resultsmentioning

confidence: 99%

Improving the Prediction of Pharmacogenes Using Text-Derived Drug-Gene Relationships

Garten¹,

Tatonetti²,

Altman³

2009

Biocomputing 2010

View full text Add to dashboard Cite

A critical goal of pharmacogenomics research is to identify genes that can explain variation in drug response. We have previously reported a method that creates a genome-scale ranking of genes likely to interact with a drug. The algorithm uses information about drug structure and indications of use to rank the genes. Although the algorithm has good performance, its performance depends on a curated set of drug-gene relationships that is expensive to create and difficult to maintain. In this work, we assess the utility of text mining in extracting a network of drug-gene relationships automatically. This provides a valuable aggregate source of knowledge, subsequently used as input into the algorithm that ranks potential pharmacogenes. Using a druggene network created from sentence-level co-occurrence in the full text of scientific articles, we compared the performance to that of a network created by manual curation of those articles. Under a wide range of conditions, we show that a knowledge base derived from text-mining the literature performs as well as, and sometimes better than, a high-quality, manually curated knowledge base. We conclude that we can use relationships mined automatically from the literature as a knowledgebase for pharmacogenomics relationships. Additionally, when relationships are missed by text mining, our system can accurately extrapolate new relationships with 77.4% precision.

show abstract

Antidepressant Switching Among Adherent Patients Treated for Depression

Abstract: Among adults with depression starting antidepressant therapy, medication switching commonly occurs during the first three months of treatment. Greater clinical severity and low initial dosing may increase the risk of switching antidepressants.

Cited by 12 publications

References 31 publications

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database

Improving the Prediction of Pharmacogenes Using Text-Derived Drug-Gene Relationships

Contact Info

Product

Resources

About